

Richard LeBlanc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2389724/publications.pdf>

Version: 2024-02-01

29
papers

944
citations

1040056

9
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

1488
citing authors

#	ARTICLE	IF	CITATIONS
1	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
2	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. <i>Blood</i> , 2020, 135, 1833-1846.	1.4	42
3	IgD Heavy-Chain Deposition Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 784-790.	6.1	35
4	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. <i>British Journal of Cancer</i> , 2022, 126, 718-725.	6.4	21
5	Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. <i>Blood</i> , 2016, 128, 977-977.	1.4	15
6	Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8510-8510.	1.6	15
7	Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8018-8018.	1.6	13
8	Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8530-8530.	1.6	13
9	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i> e41-e56.	0.4	11
10	The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. <i>Haematologica</i> , 2021, 106, 1733-1736.	3.5	11
11	Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	2.5	9
12	Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2748-2748.	1.4	8
13	Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8038-8038.	1.6	6
14	Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3330-3330.	1.4	6
15	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. <i>Bone Marrow Transplantation</i> , 2022, 57, 252-260.	2.4	6
16	Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 3.	6.2	5
17	Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427.	2.2	4
18	Atypical Chronic Lymphocytic Leukemia with CD200 Expression Shares Similar Outcomes to Classical Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 5572-5572.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Newly diagnosed multiple myeloma patients treated with tandem autoallogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. <i>Clinical Transplantation</i> , 2020, 34, e14099.	1.6	4
20	Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617.	0.4	4
21	FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8524-8524.	1.6	3
22	Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. <i>Blood</i> , 2021, 138, 2751-2751.	1.4	3
23	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342.	2.8	3
24	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582.	2.2	3
25	Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. <i>British Journal of Haematology</i> , 2022, 198, 93-102.	2.5	3
26	The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 106, 673-681.	2.2	2
27	Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (±CD38 mAbs).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20020-e20020.	1.6	0
28	Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2021, 138, 4721-4721.	1.4	0
29	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 5-7.	1.4	0